SNTI
ANALYST COVERAGE4 analysts
BUY
+509.7%upside to target
Buy
250%
Hold
250%
2 Buy (50%)2 Hold (50%)0 Sell (0%)
Full report →
PRICE
Prev Close
0.98
Open
1.00
Day Range0.95 – 1.01
0.95
1.01
52W Range0.77 – 3.88
0.77
3.88
7% of range
VOLUME & SIZE
Avg Volume
169.4K
FUNDAMENTALS
P/E Ratio
-0.7x
Not profitable
EPS (TTM)
Div Yield
No dividend
TECHNICAL
RSI (14)
42
Bearish momentum
Upcoming Events
EEarnings Report
Tomorrow
May 23
DEx-Dividend
In 90 days
Aug 20
PDividend Pay
In 116 days
Sep 15

SNTI News

About

senti biosciences is a team of engineers, scientists, and entrepreneurs on a mission to leverage synthetic biology to treat the most pressing diseases. they have pioneered new technology platforms to design synthetic gene circuits for adaptive cell and gene therapies. their recently completed series a round of funding will be used to further the growth of their scalable therapeutic design platform and advance therapeutic candidates towards the clinic. they are proud to count nea, 8vc, amgen ventures, pear ventures, lux capital, menlo ventures, allen & company, nest.bio, omega funds, goodman capital, and lifeforce capital among their investors.

Industry
Research and Development in Biotechnology (except Nanobiotechnology)
James J. CollinsScientific Co-Founder, Chairperson of Scientific Advisory Board & Independent Director
Kanya RajangamPresident, Head of Research & Development and Chief Medical Officer
Faraz SiddiquiSenior Vice President of Technical Operations
Jay CrossChief Financial Officer
Robert H. CutlerSenior Vice President & Head of Legal Affairs
Timothy K. LuCo-Founder, Chief Executive Officer & Director
Wilson WongScientific Co-Founder & Member of Scientific Advisory Board
Thomas ChungVice President of Strategic Finance & Corporate Development
Dee Olomajeye DragonSenior VP of People & Culture Strategy & Head of Administrative Operations